Pearce IP BioBlast™: w/e 06 March 2020

by , | Mar 9, 2020

Significant biosimilar activities this week include

02 Mar 20 | Celltrion launched Remsima SC, its subcutaneous infliximab product, in the UK. To support the launch, Celltrion held a symposium at which it showcased the product and supporting data. Celltrion has signed a framework agreement with the NHS to supply the product.

03 Mar 20 | China’s National Health Commission released new treatment guidelines for SARS-CoV-2 which included the use of Roche’s Actemra (tocilizumab) to treat patients with serious lung damage and high IL-6 levels. At this stage, there is no clinical trial evidence that shows the drug will be effective on coronavirus, however clinical trials are ongoing, with trials expected to end on May 10. The product is yet to be approved for use in treating patients with SARS-CoV-2.

 05 Mar 20 | The Federal Circuit Court affirmed the District Court’s judgement of non-infringement in the Celltrion v Janssen (infliximab) matter.

06 Mar 20 | In its 2019 Q4 earnings call, Mylan announced the FDA has accepted its aBLA for a proposed bevacizumab biosimilar. The FDA’s decision is expected on or before December 27, 2020.

Get our Pearce IP Blogs & BioBlast™ sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast™ to recieve our updates via email.

Our Latest News